- Home
- GDYN vs GERN Comparison
GDYN vs GERN Comparison
Compare GDYN & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDYN
- GERN
- Stock Information
- Founded
- GDYN 2006
- GERN 1990
- Country
- GDYN United States
- GERN United States
- Employees
- GDYN N/A
- GERN N/A
- Industry
- GDYN Computer Software: Prepackaged Software
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- GDYN Technology
- GERN Health Care
- Exchange
- GDYN Nasdaq
- GERN Nasdaq
- Market Cap
- GDYN 727.6M
- GERN 740.5M
- IPO Year
- GDYN N/A
- GERN 1996
- Fundamental
- Price
- GDYN $8.73
- GERN $1.20
- Analyst Decision
- GDYN Strong Buy
- GERN Buy
- Analyst Count
- GDYN 4
- GERN 7
- Target Price
- GDYN $11.25
- GERN $3.00
- AVG Volume (30 Days)
- GDYN 1.3M
- GERN 8.8M
- Earning Date
- GDYN 10-30-2025
- GERN 11-05-2025
- Dividend Yield
- GDYN N/A
- GERN N/A
- EPS Growth
- GDYN 457.52
- GERN N/A
- EPS
- GDYN 0.16
- GERN N/A
- Revenue
- GDYN $405,955,000.00
- GERN $183,403,000.00
- Revenue This Year
- GDYN $20.14
- GERN $166.20
- Revenue Next Year
- GDYN $10.10
- GERN $55.83
- P/E Ratio
- GDYN $53.50
- GERN N/A
- Revenue Growth
- GDYN 23.63
- GERN 522.13
- 52 Week Low
- GDYN $7.37
- GERN $1.04
- 52 Week High
- GDYN $25.50
- GERN $4.21
- Technical
- Relative Strength Index (RSI)
- GDYN 55.41
- GERN 52.29
- Support Level
- GDYN $7.98
- GERN $1.05
- Resistance Level
- GDYN $8.62
- GERN $1.28
- Average True Range (ATR)
- GDYN 0.35
- GERN 0.07
- MACD
- GDYN 0.01
- GERN 0.01
- Stochastic Oscillator
- GDYN 67.59
- GERN 66.67
About GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.